CZ297632B6 - Zlepsené farmaceutické kompozice - Google Patents

Zlepsené farmaceutické kompozice Download PDF

Info

Publication number
CZ297632B6
CZ297632B6 CZ0202599A CZ202599A CZ297632B6 CZ 297632 B6 CZ297632 B6 CZ 297632B6 CZ 0202599 A CZ0202599 A CZ 0202599A CZ 202599 A CZ202599 A CZ 202599A CZ 297632 B6 CZ297632 B6 CZ 297632B6
Authority
CZ
Czechia
Prior art keywords
water
oil
suspension
composition
pharmaceutical composition
Prior art date
Application number
CZ0202599A
Other languages
Czech (cs)
English (en)
Other versions
CZ202599A3 (cs
Inventor
P. Foster@Tood
L. Kiefer@David
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25194373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ297632(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of CZ202599A3 publication Critical patent/CZ202599A3/cs
Publication of CZ297632B6 publication Critical patent/CZ297632B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CZ0202599A 1996-12-09 1997-12-03 Zlepsené farmaceutické kompozice CZ297632B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/806,584 US5736151A (en) 1996-12-09 1996-12-09 Antibiotic oil suspensions

Publications (2)

Publication Number Publication Date
CZ202599A3 CZ202599A3 (cs) 1999-09-15
CZ297632B6 true CZ297632B6 (cs) 2007-02-14

Family

ID=25194373

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ0202599A CZ297632B6 (cs) 1996-12-09 1997-12-03 Zlepsené farmaceutické kompozice

Country Status (21)

Country Link
US (1) US5736151A (enExample)
EP (1) EP0941095B1 (enExample)
JP (1) JP2001505910A (enExample)
KR (1) KR100544248B1 (enExample)
CN (1) CN100413506C (enExample)
AT (1) ATE264681T1 (enExample)
AU (1) AU746666B2 (enExample)
BR (1) BR9714967B1 (enExample)
CA (1) CA2269682C (enExample)
CZ (1) CZ297632B6 (enExample)
DE (1) DE69728783T2 (enExample)
DK (1) DK0941095T3 (enExample)
ES (1) ES2218705T3 (enExample)
FI (1) FI991302L (enExample)
HU (1) HUP0000564A3 (enExample)
NO (1) NO325475B1 (enExample)
NZ (1) NZ336183A (enExample)
PL (1) PL190662B1 (enExample)
PT (1) PT941095E (enExample)
SK (1) SK72399A3 (enExample)
WO (1) WO1998025621A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60136367D1 (de) * 2000-09-12 2008-12-11 Pharmacia & Upjohn Co Llc Pharmazeutische zusammensetzung mit modifiziertem träger
US7829100B2 (en) * 2000-09-12 2010-11-09 Teagarden Dirk L Pharmaceutical composition having modified carrier
KR100423895B1 (ko) * 2001-02-19 2004-03-24 주식회사 엘지생명과학 셉티오퍼 하이드로클로라이드의 현탁제 조성물
US20040022815A1 (en) * 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
EP1528926A1 (en) * 2002-08-07 2005-05-11 Orchid Health Care Novel pharmaceutical composition of ceftiofur
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
US7659061B2 (en) * 2002-11-19 2010-02-09 Pharmacia & Upjohn Company Pharmaceutical compositions having a modified vehicle
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
DE602004002201T2 (de) * 2003-03-20 2007-09-20 Pharmacia Corp. Dispergierbare pharmazeutische zusammensetzung eines entzündungshemmers
CA2529405A1 (en) * 2003-07-31 2005-02-03 Pharmacia & Upjohn Company Llc Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
WO2006008640A1 (en) * 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
CZ300424B6 (cs) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
CZ300590B6 (cs) * 2006-06-20 2009-06-24 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
AU2008215659B2 (en) 2007-02-16 2012-11-01 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
CN101406447B (zh) * 2007-10-12 2010-08-25 河南农业大学 复方头孢噻呋油混悬注射液制备工艺
US20100087481A1 (en) * 2008-10-03 2010-04-08 Lee Kathleen M Oral pharmaceutical formulations for antidiabetic compounds
BRPI0922041A8 (pt) * 2008-11-19 2022-08-16 Merial Ltd Formulações compreendendo ceftiofur e cetoprofeno ou cetiofur e álcool benzílico.
EP2874624B8 (en) 2012-07-17 2019-10-02 Bayer New Zealand Limited Injectable antibiotic formulations and their methods of use
FR3000392B1 (fr) 2012-12-27 2015-03-27 Virbac Nouvelles compositions pharmaceutiques veterinaires et leur procede de preparation
CN106456704A (zh) 2014-04-16 2017-02-22 Veyx-药物有限公司 兽药组合物和其应用
WO2016144862A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
WO2018071810A1 (en) 2016-10-13 2018-04-19 RhinoNase, Inc. Antibiotic compositions for nasal irrigation and methods
KR20200036808A (ko) 2017-04-03 2020-04-07 코히러스 바이오사이언시스, 인크. 진행성 핵상 마비 치료를 위한 PPARγ 작용제
CN113209015A (zh) * 2020-01-21 2021-08-06 江西邦诚动物药业有限公司 长效盐酸头孢噻呋混悬注射液及其制备工艺

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB914894A (en) * 1960-08-12 1963-01-09 Beecham Res Lab Injectable pharmaceutical media
GB955891A (en) * 1961-01-31 1964-04-22 Organon Labor Ltd Stable preparations of prednisone derivatives and process for the manufacture thereof
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4464367A (en) * 1980-03-26 1984-08-07 Sanofi Cephalosporin derivatives, process for preparation thereof and drugs containing said derivatives usable as antibiotics
US4902683A (en) * 1984-10-25 1990-02-20 The Upjohn Company Crystalline cephalosporin hydrohalide salts
WO1991008734A1 (en) * 1989-06-13 1991-06-27 Abbott Laboratories Anhydrous oil-based liquid suspension for delivering a medicament
WO1994020505A1 (en) * 1993-03-12 1994-09-15 The Upjohn Company Crystalline ceftiofur free acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937330A (en) * 1985-08-12 1990-06-26 The Upjohn Company Conversion of cephalosporin hydrohalide salt to alkali metal salt
EP0393066B1 (en) * 1987-11-10 1994-02-02 The Upjohn Company Cephalosporin antibiotics
US5223496A (en) * 1987-11-10 1993-06-29 The Upjohn Company Cephalosporin antibiotics
US4877782A (en) * 1988-02-16 1989-10-31 The Upjohn Company Zinc ceftiofur complexes

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB914894A (en) * 1960-08-12 1963-01-09 Beecham Res Lab Injectable pharmaceutical media
GB955891A (en) * 1961-01-31 1964-04-22 Organon Labor Ltd Stable preparations of prednisone derivatives and process for the manufacture thereof
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4464367A (en) * 1980-03-26 1984-08-07 Sanofi Cephalosporin derivatives, process for preparation thereof and drugs containing said derivatives usable as antibiotics
US4902683A (en) * 1984-10-25 1990-02-20 The Upjohn Company Crystalline cephalosporin hydrohalide salts
WO1991008734A1 (en) * 1989-06-13 1991-06-27 Abbott Laboratories Anhydrous oil-based liquid suspension for delivering a medicament
WO1994020505A1 (en) * 1993-03-12 1994-09-15 The Upjohn Company Crystalline ceftiofur free acid

Also Published As

Publication number Publication date
NO992780D0 (no) 1999-06-08
FI991302A0 (fi) 1999-06-08
CN1238690A (zh) 1999-12-15
KR100544248B1 (ko) 2006-01-23
US5736151A (en) 1998-04-07
CA2269682C (en) 2009-04-14
JP2001505910A (ja) 2001-05-08
BR9714967B1 (pt) 2010-06-29
WO1998025621A1 (en) 1998-06-18
ATE264681T1 (de) 2004-05-15
CA2269682A1 (en) 1998-06-18
DE69728783D1 (de) 2004-05-27
DE69728783T2 (de) 2005-03-31
EP0941095A1 (en) 1999-09-15
AU5452998A (en) 1998-07-03
NZ336183A (en) 2000-12-22
SK72399A3 (en) 2000-05-16
NO992780L (no) 1999-06-08
NO325475B1 (no) 2008-05-13
HUP0000564A2 (hu) 2000-10-28
HK1023292A1 (zh) 2000-09-08
KR20000069360A (ko) 2000-11-25
PL190662B1 (pl) 2005-12-30
CN100413506C (zh) 2008-08-27
ES2218705T3 (es) 2004-11-16
PT941095E (pt) 2004-08-31
FI991302A7 (fi) 1999-06-08
HUP0000564A3 (en) 2001-01-29
FI991302L (fi) 1999-06-08
EP0941095B1 (en) 2004-04-21
DK0941095T3 (da) 2004-08-02
AU746666B2 (en) 2002-05-02
BR9714967A (pt) 2001-10-30
CZ202599A3 (cs) 1999-09-15

Similar Documents

Publication Publication Date Title
CZ297632B6 (cs) Zlepsené farmaceutické kompozice
HK1023292B (en) Improved pharmaceutical compositions
US12295958B2 (en) Ready-to-use injectable formulations
RU2777360C9 (ru) Готовые к применению лекарственные формы для инъекций
RU2777360C1 (ru) Готовые к применению лекарственные формы для инъекций
JP6189437B2 (ja) 注射用抗生物質製剤およびその使用方法
KR960008236B1 (ko) 세파로스포린계 항생제의 수성 조성물 및 그 제조방법
AU2024278169A1 (en) Controlled Release Compositions and their Methods of Use
JPS6121618B2 (enExample)
US9452155B2 (en) Injectable antibiotic formulations and their methods of use
NZ613138A (en) Injectable antibiotic formulations and their methods of use

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20091203